Stock Analiz

CapsoVision, Inc CV

Biotechnology: Electromedical & Electrotherapeutic Apparatus · IPO 2025 · data as of November 13, 2026

$6.03Market cap $323M
Open the interactive analysis →

CapsoVision, Inc (CV) is a healthcare company listed in the US with a market value of about $323M. In the twelve months to September 30, 2026 it had revenue of $14M and net income of -$29M, a net margin of -210.1%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -142%.

About CapsoVision

CapsoVision is listed in the US and classified in biotechnology: electromedical & electrotherapeutic apparatus, IPO year 2025. It was profitable in 0 of the last 2 years in our data. It spends 135% of revenue on research and development.

Score: 0.8 / 5

Value0/5
Future growth2/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S23.2
P/B12.3
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-9.1%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)15.3%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-178.0%
ROIC (5-yr avg.)-142.5%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 2 years

Fiscal yearTTM20252024
Revenue$14M$14M$12M
Net income-$29M-$25M-$20M
Free cash flow-$29M-$23M-$20M
EPS (diluted)$-0.43$-1.03$-9.85
Net margin-210.1%-186.8%-169.3%
ROIC—-142.5%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 2 analysts is $9.50, 58% above the current price; targets range from $9.00 to $10.00; the consensus rating is “Strong buy”; expected EPS is $-0.56 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does CapsoVision pay a dividend?

Not currently.

Is CapsoVision a good stock to buy?

We do not give buy or sell advice. CapsoVision scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.